Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study

Ralph W deVere White, Arline D. Deitch, Henry Tesluk, Brent Blumenstein, Bruce A. Lowe, Arthur I. Sagalowsky, Joseph A. Smith, Paul F. Schellhammer, Thomas H. Stanisic, H. Barton Grossman, Edward Messing, John D. Crissman, E. David Crawford

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

While 80% of transitional cell carcinomas (TCC) present as Ta/Tl lesions, they account for only 15% of deaths caused by TCC. We have evaluated the ability of DNA ploidy analysis to predict outcome in 228 patients with Ta/Tl TCC. All patients were judged to be at increased risk for tumor recurrence due to having two occurrences of Stage Tl tumor within 56 weeks, or three or more tumors presenting simultaneously within 16 weeks of registration. Concurrent carcinoma in situ was acceptable. All patients were treated with either bacillus Calmette Guerin (BCG) immunotherapy or mitomycin-C (MMC) intravesical chemotherapy. Patients with nondiploid tumors had higher hazard rates for both tumor progression and death (p = 0.007 and p = 0.016, respectively); however, the prognostic information of DNA ploidy was not additive to tumor grade.

Original languageEnglish (US)
Pages (from-to)27-34
Number of pages8
JournalUrologic Oncology
Volume2
Issue number1
DOIs
StatePublished - Jan 1996

Fingerprint

Ploidies
Urinary Bladder Neoplasms
Transitional Cell Carcinoma
DNA
Neoplasms
Carcinoma in Situ
Mitomycin
Mycobacterium bovis
Immunotherapy
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

deVere White, R. W., Deitch, A. D., Tesluk, H., Blumenstein, B., Lowe, B. A., Sagalowsky, A. I., ... Crawford, E. D. (1996). Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study. Urologic Oncology, 2(1), 27-34. https://doi.org/10.1016/1078-1439(96)00031-2

Prognostic significance of DNA ploidy in Ta/Tl bladder cancer : A southwest oncology group study. / deVere White, Ralph W; Deitch, Arline D.; Tesluk, Henry; Blumenstein, Brent; Lowe, Bruce A.; Sagalowsky, Arthur I.; Smith, Joseph A.; Schellhammer, Paul F.; Stanisic, Thomas H.; Grossman, H. Barton; Messing, Edward; Crissman, John D.; Crawford, E. David.

In: Urologic Oncology, Vol. 2, No. 1, 01.1996, p. 27-34.

Research output: Contribution to journalArticle

deVere White, RW, Deitch, AD, Tesluk, H, Blumenstein, B, Lowe, BA, Sagalowsky, AI, Smith, JA, Schellhammer, PF, Stanisic, TH, Grossman, HB, Messing, E, Crissman, JD & Crawford, ED 1996, 'Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study', Urologic Oncology, vol. 2, no. 1, pp. 27-34. https://doi.org/10.1016/1078-1439(96)00031-2
deVere White, Ralph W ; Deitch, Arline D. ; Tesluk, Henry ; Blumenstein, Brent ; Lowe, Bruce A. ; Sagalowsky, Arthur I. ; Smith, Joseph A. ; Schellhammer, Paul F. ; Stanisic, Thomas H. ; Grossman, H. Barton ; Messing, Edward ; Crissman, John D. ; Crawford, E. David. / Prognostic significance of DNA ploidy in Ta/Tl bladder cancer : A southwest oncology group study. In: Urologic Oncology. 1996 ; Vol. 2, No. 1. pp. 27-34.
@article{f4d79fe77f054f1ea7d39a850d08f007,
title = "Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study",
abstract = "While 80{\%} of transitional cell carcinomas (TCC) present as Ta/Tl lesions, they account for only 15{\%} of deaths caused by TCC. We have evaluated the ability of DNA ploidy analysis to predict outcome in 228 patients with Ta/Tl TCC. All patients were judged to be at increased risk for tumor recurrence due to having two occurrences of Stage Tl tumor within 56 weeks, or three or more tumors presenting simultaneously within 16 weeks of registration. Concurrent carcinoma in situ was acceptable. All patients were treated with either bacillus Calmette Guerin (BCG) immunotherapy or mitomycin-C (MMC) intravesical chemotherapy. Patients with nondiploid tumors had higher hazard rates for both tumor progression and death (p = 0.007 and p = 0.016, respectively); however, the prognostic information of DNA ploidy was not additive to tumor grade.",
author = "{deVere White}, {Ralph W} and Deitch, {Arline D.} and Henry Tesluk and Brent Blumenstein and Lowe, {Bruce A.} and Sagalowsky, {Arthur I.} and Smith, {Joseph A.} and Schellhammer, {Paul F.} and Stanisic, {Thomas H.} and Grossman, {H. Barton} and Edward Messing and Crissman, {John D.} and Crawford, {E. David}",
year = "1996",
month = "1",
doi = "10.1016/1078-1439(96)00031-2",
language = "English (US)",
volume = "2",
pages = "27--34",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Prognostic significance of DNA ploidy in Ta/Tl bladder cancer

T2 - A southwest oncology group study

AU - deVere White, Ralph W

AU - Deitch, Arline D.

AU - Tesluk, Henry

AU - Blumenstein, Brent

AU - Lowe, Bruce A.

AU - Sagalowsky, Arthur I.

AU - Smith, Joseph A.

AU - Schellhammer, Paul F.

AU - Stanisic, Thomas H.

AU - Grossman, H. Barton

AU - Messing, Edward

AU - Crissman, John D.

AU - Crawford, E. David

PY - 1996/1

Y1 - 1996/1

N2 - While 80% of transitional cell carcinomas (TCC) present as Ta/Tl lesions, they account for only 15% of deaths caused by TCC. We have evaluated the ability of DNA ploidy analysis to predict outcome in 228 patients with Ta/Tl TCC. All patients were judged to be at increased risk for tumor recurrence due to having two occurrences of Stage Tl tumor within 56 weeks, or three or more tumors presenting simultaneously within 16 weeks of registration. Concurrent carcinoma in situ was acceptable. All patients were treated with either bacillus Calmette Guerin (BCG) immunotherapy or mitomycin-C (MMC) intravesical chemotherapy. Patients with nondiploid tumors had higher hazard rates for both tumor progression and death (p = 0.007 and p = 0.016, respectively); however, the prognostic information of DNA ploidy was not additive to tumor grade.

AB - While 80% of transitional cell carcinomas (TCC) present as Ta/Tl lesions, they account for only 15% of deaths caused by TCC. We have evaluated the ability of DNA ploidy analysis to predict outcome in 228 patients with Ta/Tl TCC. All patients were judged to be at increased risk for tumor recurrence due to having two occurrences of Stage Tl tumor within 56 weeks, or three or more tumors presenting simultaneously within 16 weeks of registration. Concurrent carcinoma in situ was acceptable. All patients were treated with either bacillus Calmette Guerin (BCG) immunotherapy or mitomycin-C (MMC) intravesical chemotherapy. Patients with nondiploid tumors had higher hazard rates for both tumor progression and death (p = 0.007 and p = 0.016, respectively); however, the prognostic information of DNA ploidy was not additive to tumor grade.

UR - http://www.scopus.com/inward/record.url?scp=0029785951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029785951&partnerID=8YFLogxK

U2 - 10.1016/1078-1439(96)00031-2

DO - 10.1016/1078-1439(96)00031-2

M3 - Article

C2 - 21224132

AN - SCOPUS:0029785951

VL - 2

SP - 27

EP - 34

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 1

ER -